chinese pharmaceutical companies are turning their attention to innovation, shifting rapidly from mastery of follow-on drugs to researching first-in-class and best-in-class drugs. aiming to be a healthcare group with a global presence, fosun pharma, established in shanghai in 1994, has built its core business around innovative drug r&d and manufacturing.
innovation for health — the fourth hongqiao international health technology innovation forum held in shanghai
on november 6, 2021, as a parallel supporting event of the 4th china international import expo (ciie), the 4th hongqiao international health technology innovation forum with the theme of "innovation for good health" was successfully held. this forum was sponsored by the international health exchange and cooperation center nhc prc (ihecc) and china pharmaceutical innovation and research development association,
2021 csco | henlius publishes newest phase ii clinical data of novel anti-pd-1 mab serplulimab for treatment of advanced cervical cancer
in this meeting, henlius releases phase 2 study results of serplulimab (hlx10, novel anti-pd-1 antibody), in patients with advanced cervical cancer in an oral presentation.
2021 csco | henlius publishes phase iii clinical data of bevacizumab biosimilar hlx04 for treatment of metastatic colorectal cancer
in this meeting, henlius releases phase 3 study results of hlx04 (bevacizumab biosimilar), in patients with metastatic colorectal cancer in an oral presentation.
shanghai henlius biotech, inc.
henlius (2696. hk) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. since its inception in 2010, henlius has built an integrated biopharmaceutical platform with core capabilities of high efficiency and innovation embedded throughout the whole product life cycle including r&d, manufacturing and commercialization. it has established global innovation centers and a shanghai-based manufacturing facility certificated by china and the eu good manufacturing practice (gmp).
shanghai henlius biotech, inc.
henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mabs) and has continued to explore immuno-oncology combination therapies with proprietary hlx10 (anti-pd-1 mab) as backbone. up to date, the company has successfully marketed 3 innovative monoclonal antibodies (mabs), including 汉利康ⓡ (rituximab), the first china-developed biosimilar, 汉曲优® (trastuzumab, zercepac in the eu), the first china-developed mab biosimilar approved both in china and in the eu, and 汉达远® (adalimumab), the first autoimmune disease treatment product developed by the company. in addition, the nda of hlx04 bevacizumab and hlx01 rituximab for new indications of rheumatoid arthritis is under review. henlius has also concurrently carried out more than 20 clinical trials on 10 products and 8 combination regimens worldwide. the external authorization of the products fully covers the mainstream biopharmaceutical markets in europe and the united states, as well as many emerging countries.